Discontinued — last reported Q3 '17

Other

Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1

Year-over-year, this metric grew by 173.6%, from $2.30M to $6.28M. Over 3 years (FY 2021 to FY 2025), Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 shows an upward trend with a 59.7% CAGR.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2015
Last reportedQ3 2017
Metric ID: other_noncash_or_part_noncash_acquisition_value_of_liabi_247af8

Historical Data

16 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25
Value$385.75K$0.00$2.49M$0.00$2.18M$3.98M$140.80M$3.35M$5.33M$76.00K$0.00$2.30M$0.00$0.00$0.00$6.28M
QoQ Change—-100.0%—-100.0%—+82.3%>999%-97.6%+58.8%-98.6%-100.0%—-100.0%———
YoY Change————+465.1%—>999%—+34.0%-99.9%-100.0%—-100.0%-100.0%—+173.6%
Range$0.00 – $140.80M
CAGR+110.4%
Avg YoY Growth+727.9%
Median YoY Growth-33.0%

Frequently Asked Questions

What is ResMed's noncash or part noncash acquisition value of liabilities assumed1?
ResMed (RMD) reported noncash or part noncash acquisition value of liabilities assumed1 of $6.28M in Q2 2025.
How has ResMed's noncash or part noncash acquisition value of liabilities assumed1 changed year-over-year?
ResMed's noncash or part noncash acquisition value of liabilities assumed1 increased by 173.6% year-over-year, from $2.30M to $6.28M.
What is the long-term trend for ResMed's noncash or part noncash acquisition value of liabilities assumed1?
Over 3 years (2021 to 2025), ResMed's noncash or part noncash acquisition value of liabilities assumed1 has grown at a 59.7% compound annual growth rate (CAGR), from $1.54M to $6.28M.